A double blind, randomized, active-control study to evaluate effects of drospirenone/estradiol (Angeliq) and medroxyprogesterone acetate/conjugated equine estrogen (Prempro) on blood pressure and sodium sensitivity in postmenopausal women with prehypertension

Trial Profile

A double blind, randomized, active-control study to evaluate effects of drospirenone/estradiol (Angeliq) and medroxyprogesterone acetate/conjugated equine estrogen (Prempro) on blood pressure and sodium sensitivity in postmenopausal women with prehypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Estradiol/drospirenone (Primary) ; Conjugated estrogens/medroxyprogesterone
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.; Berlex
  • Most Recent Events

    • 09 Mar 2010 Bayer Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Actual patient number (92) added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top